PET/MRI in Prostate Cancer - The PRISTINE Study
Research type
Research Study
Full title
PET/MRI (Positron Emission Tomography/Magnetic Resonance Imaging) to Improve Staging and Personalise Treatment for Prostate Cancer: PRISTINE Study
IRAS ID
312365
Contact name
Rishikesan Ramaesh
Contact email
Sponsor organisation
University of Edinburgh
Duration of Study in the UK
2 years, 0 months, 1 days
Research summary
PRISTINE is a prospective cohort study based at the Edinburgh Cancer Centre and we are particularly interested in patients who are undergoing surgery for the first time for their prostate cancer
Patients will be recruited from the regional uro-oncology meeting and will be receive their standard diagnostic tests which would include an MRI, a bone scan and a biopsy along with blood markers. Their case will be discussed at the regional prostate cancer meetings and those who are eligible for surgery, a procedure called a radical prostatectomy, will be invited to take part in PRISTINE.
Those who agree to take part will undergo a further special type of examination called a PSMA PET/MRI which involves a MRI scan and a PET scan of the prostate done together. This additional scan will take about 45 minutes and be done at the Edinburgh Imaging Centre. Following surgery, we will compare the results of the surgical specimens with the imaging results to understand how accurately the PSMA PET/MRI has detected disease. This will be done using a side by side analysis of the pathology slides with the scan images and the radiologists will be blinded to the results of the pathology.
We will use advanced computer analysis to develop and identify key imaging markers that can help doctors tailor treatment and identify those who will benefit the most.
REC name
South East Scotland REC 02
REC reference
23/SS/0076
Date of REC Opinion
7 Aug 2023
REC opinion
Further Information Favourable Opinion